Viridian Therapeutics, Inc./DE Notes Payable
Viridian Therapeutics, Inc./DE (VRDN) had Notes Payable of $7.37 million as of 2020-03-31, per its 10-Q filed 2020-05-08.
Discontinued › Balance Sheet › Liabilities › Long-Term Debt, Unclassified
us-gaap:NotesPayable · last filed 2020-05-08
- 2020-03-31: Notes Payable $7.37M.
- 2019-12-31: Notes Payable $8.30M.
- 2019-09-30: Notes Payable $9.23M.
- 2019-06-30: Notes Payable $10.15M.
| Period end | Notes Payable |
|---|---|
| 2020-03-31 | $7.37M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $8.30M 10-Q · filed 2020-05-08 |
| 2019-09-30 | $9.23M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $10.15M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $10.39M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $10.30M 10-K · filed 2020-03-13 |
| 2018-09-30 | $10.21M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $10.11M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $10.02M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $9.92M 10-K · filed 2019-03-14 |
| 2017-09-30 | $3.37M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $3.85M 10-Q · filed 2017-08-11 |
| 2017-03-31 | $4.32M 10-Q · filed 2017-05-11 |
| 2016-12-31 | $4.79M 10-K · filed 2018-03-15 |
| 2014-09-30 | $11.00K 10-Q · filed 2014-11-14 |
| 2014-06-30 | $11.00K 10-Q · filed 2014-08-14 |
| 2013-12-31 | $42.00K 10-Q · filed 2014-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |